GJD3

Across TCGA pan-cancer cohorts, GJD3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GJD3 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GJD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GJD3 expression acts as an unfavorable survival marker.

LUSC and LUAD are the cancer types where GJD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.031	0.776	<.001	24	view →
LUAD	OS	Median	All	0.090	0.812	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

GJD3–LUSC (OS)

Open the LUSC breakdown →